Cancer/Tumour profiling is obtaining knowledge about patient’s cancer/tumour profile that is able to identify genomic alterations which can help physician to select an appropriate therapy which can result successful treatment for the patient. This is expected to reduce trial and error process and increase the likelihood of treatment being successful on individual basis. Different tests such as blood tests, Barium X-ray, cystoscopy, bone marrow, and lumbar puncture are used in diagnosis of specific types of cancer. Different treatments available for cancer are hormone therapy, surgery, bisphosphonates, radiotherapy, chemotherapy, biological therapies, and bone marrow and stem cell transplants.Increasing number of cancer cases is expected to be the major driver for this market. Technological advancements for identifying the exact cause of the condition is also expected to drive the market. Increasing awareness, investment in healthcare facilities, demand for safe and cost effective treatment, mainly in developing economies of Asia Pacific region, are expected to be market drivers. However, lack of awareness of options and potential of cancer/tumor profiling among clinicians may pose severe challenge for this market. Point of care diagnostic test and development of personalized medicine for cancer have been new trends in the market.
By application; market is segmented into diagnostic, disease prognosis, research, biomarker discovery and personalized medicine applications; of which personalized medicine has been the largest revenue sector and is expected to be the fastest growing segment. Disease prognosis, early diagnosis and research applications are expected to support the market growth.
By technology; market is segmented as immunohistochemistry, microarray, next-generation sequencing, FISH/CISH and quantitative PCR. Segment types are proteomics, genomics, epigenetics and metabolomics.
By region; cancer/tumor market is segmented into North America, Europe, Asia Pacific and RoW. North America has been the major contributor to this market. Europe has been the next major contributor due to better research and development facilities and presence of technology providers. High growth is expected in developing economies such as India, China, Japan and other areas of Asia Pacific. High growth is expected in untapped European markets due to their growing GDP and demand for cost effective and safe diagnostics and therapeutics.
Key players in cancer/tumor profiling market are Life Technologies Corporation (U.S.), RiboMed Biotechnologies Inc. (U.S.), Caris Life Sciences (U.S.), Rational Therapeutics (U.S.), NeoGenomics Laboratories (U.S.), Oncopath Laboratories (U.S.), Genomic Health Inc. (U.S.), Boreal Genomics Inc. (U.S.), Nanostring Technologies (U.S.), Oxford Gene Technology Ltd. (U.K.), Illumina, Inc. (U.S.), Agendia (The Netherlands), BioTheranostics (U.S.), Precision Therapeutics Inc. (U.S.), and Proteome Sciences PLC (U.K.).
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.